Skip to content
sellWeak cluster of 210b5-1 plan

John Kenneth Jenkins sold $20k of CRBP

director at Corbus Pharmaceuticals Holdings, Inc.. 2,783 shares at an average of $7.35, traded May 30, 2025, filed Jun 2, 2025.

Warning score
23
Value
$20k
2,783 shares
Holdings after
33
-99% from before
From 52-week low
+51%
low $4.92, close $7.42
From 52-week high
-87%
high $55.81, as of May 30, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $20k at market
    0
  • Share of holdings sold
    Sold 99% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CRBPOct 9, 2026 · close 5.38
Since filing Jun 2, 2025: -26.7%SPY +33.5% · excess -60.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000950170-25-080311, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
May 30, 2025SOpen-market sale
Common Stock, par value $0.0001 per share10b5-1
-2,783$7.35$20k33Jun 2, 2025
May 30, 2025AGrant or award
Common Stock, par value $0.0001 per share10b5-1
+4,800$0.00$04,833Jun 2, 2025
May 30, 2025AGrant or award
Stock options (right to buy)derivative10b5-1
+16,000$0.00$016,000Jun 2, 2025

Related signals

Other insiders at Corbus Pharmaceuticals Holdings, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
0Weak
CRBPsell10b5-1
Corbus Pharmaceuticals Holdings, Inc.
Yong Ben
director
$16k
2,000 shares
-18%
30Weak
CRBPsell 2
Corbus Pharmaceuticals Holdings, Inc.
Dominic Smethurst
Chief Medical Officer
$51k
6,097 shares
-6%
30Weak
CRBPsell 410b5-1
Corbus Pharmaceuticals Holdings, Inc.
Yuval Cohen
Chief Executive Officer
$108k
13,871 shares
-7%
23Weak
CRBPsell 410b5-1
Corbus Pharmaceuticals Holdings, Inc.
Sean F. Moran
Chief Financial Officer
$37k
4,701 shares
-5%
35Weak
CRBPsell 4
Corbus Pharmaceuticals Holdings, Inc.
Ian Hodgson
Chief Operating Officer
$6,253
847 shares
-2%
35Weak
CRBPsell 4
Corbus Pharmaceuticals Holdings, Inc.
Ian Hodgson
Chief Operating Officer
$20k
2,415 shares
-4%
35Weak
CRBPsell 4
Corbus Pharmaceuticals Holdings, Inc.
Dominic Smethurst
Chief Medical Officer
$27k
3,285 shares
-3%
27Weak
CRBPsell
Corbus Pharmaceuticals Holdings, Inc.
Cormorant Asset Management, LP
owner
$344k
30,029 shares
-1%
27Weak
CRBPsell 310b5-1
Corbus Pharmaceuticals Holdings, Inc.
Yuval Cohen
Chief Executive Officer
$471k
27,633 shares
-18%
19Weak
CRBPsell 310b5-1
Corbus Pharmaceuticals Holdings, Inc.
Sean F. Moran
Chief Financial Officer
$221k
12,981 shares
-15%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

John Kenneth Jenkins sold $20k of CRBP | InsiderTell